A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

StatusRecruiting
PhasePhase 2
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 26 of 137 sites
  2. Eligibility criteria revised
    • Site details revised at 26 of 137 sites
  3. Primary endpoints: details revised at 1 of 5 entries
    • Trial sites expanded: 132 → 137 locations
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 3 of 16 entries
  4. Trial sites expanded: 125 → 132 locationsv4
  5. Study sites: 16 to 125v3 Show 4 more changesShow less
    • Primary completion date: Mar 28, 2027 to Mar 8, 2027
    • Study completion date: Aug 15, 2027 to May 31, 2027
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints revised (16)
  6. Study sites: 7 to 16
    • Primary completion date: Mar 8, 2027 to Mar 28, 2027
    • Study completion date: Jul 26, 2027 to Aug 15, 2027
    • Start date changed from estimate of May 22, 2025 to May 20, 2025
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
438 trials monitored
See 32 trials at risk
Asthma
958 trials monitored
See 36 trials at risk
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 75 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over the last 6 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants will be involved in this study for up to approximately 9.5 months depending on local requirements.
Trial Details
NCT Number NCT06977581
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Asthma
Related terms Airway Obstruction, Asthma, Dyspnea, Lung Diseases, Respiratory Hypersensitivity, Respiratory Sounds, Respiratory Tract Diseases
Enrollment 252 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov